IPHA · Innate Pharma SA · Metrics
$1.39
+0.06 (+4.51%)
At close · Nov 4
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$148.56M
Shares
111.70M
Volume · Nov 4
10.67K
Avg daily vol (3M)
158.14K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
IPHA metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.43
Market cap
$148.56M
Price action
20 metricsPrice change (1W)
-10.1%
Price change (30D)
-15.8%
Price change (3M)
-25.5%
Price change (6M)
-5.0%
Price change (YTD)
-24.0%
Price change (1Y)
-30.0%
Trailing year
Price change (5Y)
-77.7%
52-week high
$2.54
52-week low
$1.17
Change from 52-week high
-47.5%
Change from 52-week low
+13.7%
Annualized volatility
99.4%
Annualized volatility (3M)
90.5%
Beta
1.7
RSI (14D)
32.9
Price vs SMA 50
-23.2%
Price vs SMA 200
-22.2%
Avg volume (3M)
158,016
Relative volume
0.4
Average dollar volume
$338,953
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
111.70M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
13.0×
reciprocal yield 7.7%
P / book
—
FCF yield
-33.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
2026-11-05
Last earnings
2026-09-17
Profitability
9 metricsGross margin
—
Operating margin
-485.2%
Trailing 12 months
Net margin
-483.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$47.59M
Net income (TTM)
−$55.36M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-436.4%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-55.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$11.44M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.8%
Year over year · more shares
Revenue CAGR (3Y)
-46.2%
Revenue CAGR (5Y)
-33.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-136.7%
Debt / equity
—
Current ratio
0.6
EBITDA (TTM)
−$54.01M
Free cash flow (TTM)
−$49.93M
Quick ratio
0.6
Interest coverage
-27.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.38M
Total assets
$39.65M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$49.73M
Capital expenditures (TTM)
$200,637
R&D (TTM)
$46.63M
SG&A (TTM)
—
Stock compensation (TTM)
$2.43M
R&D / revenue
407.6%
Stock compensation / revenue
21.2%
Ownership (13F)
9 metrics13F filers
10
13F filer change QoQ
+1
Institutional ownership
0.2%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.4%
Holder tenure
8.0
Price vs estimated holder cost
+0.2%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.1%
Latest settlement · 2.6 days to cover
Days to cover
2.6d
Short-squeeze score
56 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—